Episode 55: Developing a Maternal RSV Vaccine

April 30, 2020

Pharmaceutical Executive

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV,  currently being administered to pregnant women in trials, in the hopes of protecting their infants.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Pharmaceutical Executive Magazine

·

Episode 55: Developing a Maternal RSV Vaccine